juvenile myelomonocytic leukemia , JMML (Abkürzung)
juvenile chronic myeloid leukemia , JCML (Abkürzung)
infantile monosomy 7 syndrome

Treatment of juvenile myelomonocytic leukemia is usually stem cell transplant.

Possible signs of juvenile myelomonocytic leukemia include fever, feeling very tired, and weight loss.

Juvenile myelomonocytic leukemia and monosomy 7 will be discussed below.

Juvenile myelomonocytic leukemia is a rare childhood cancer that occurs more often in children younger than 2 years.

Children who have neurofibromatosis type 1 and males have an increased risk of developing juvenile myelomonocytic leukemia.

Treatment for juvenile myelomonocytic leukemia can include splenectomy, chemotherapy, and bone marrow transplantation.

Pinkel D: Differentiating juvenile myelomonocytic leukemia from infectious disease.

Article: Juvenile myelomonocytic leukemia.

Treatment of juvenile myelomonocytic leukemia (JMML) may include the following:

"Juvenile Myelomonocytic Leukemia."

GAB2 also plays a role in juvenile myelomonocytic leukemia (JMML).

Juvenile myelomonocytic leukemia is a childhood disease in which too many myelocytes and monocytes (immature white blood cells) are made in the bone marrow.

Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Mutations in the NF1 gene have been linked to NF-1, Juvenile myelomonocytic leukemia and Watson syndrome.

In addition to neurofibromatosis type I, mutations in NF1 can also lead to juvenile myelomonocytic leukemia, Watson syndrome, and breast cancer.

Juvenile myelomonocytic leukemia (JMML) is a serious chronic leukemia (cancer of the blood) that affects children mostly aged 4 and younger.

Aricò M, Biondi A, Pui CH: Juvenile myelomonocytic leukemia.

Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with juvenile myelomonocytic leukemia.

Juvenile myelomonocytic leukemia (JMML) is a form of leukemia that is neither chronic nor acute and occurs most often in children under the age of four.

Choong K, Freedman MH, Chitayat D, et al.: Juvenile myelomonocytic leukemia and Noonan syndrome.

Lorenzana A, Lyons H, Sawaf H, et al.: Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant.

Bergstraesser E, Hasle H, Rogge T, et al.: Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria.

Note: Juvenile myelomonocytic leukemia (JMML) was classified as a myelodysplastic syndrome (MDS) under the French-American-British scheme.

Emanuel PD, Snyder RC, Wiley T, et al.: Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

Hasle H, Aricò M, Basso G, et al.: Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7.

Juvenile myelomonocytic leukemia (JMML), formerly termed juvenile chronic myeloid leukemia, is a rare hematopoietic malignancy of childhood accounting for less than 1% of all childhood leukemias.

Emanuel PD, Bates LJ, Castleberry RP, et al.: Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.

The WHO classification schema has a subgroup that includes JMML (formerly juvenile chronic myeloid leukemia), CMML, and Ph chromosome-negative CML.

The name JMML now encompasses all diagnoses formerly referred to as Juvenile Chronic Myeloid Leukemia (JCML), Chronic Myelomonocytic Leukemia of Infancy, and Infantile Monosomy 7 Syndrome.